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Abstract
Background: Human Enterovirus 71 (EV71) is a common cause of hand, foot and mouth disease (HFMD) in young children.
It is often associated with severe neurological diseases and has caused high mortalities in recent outbreaks across the Asia
Pacific region. Currently, there is no effective vaccine and antiviral agents available against EV71 infections. VP1 is one of the
major immunogenic capsid protein of EV71 and plays a crucial role in viral infection. Antibodies against VP1 are important
for virus neutralization.
Methodology/Principal Finding: In the present study, infectious EV71 viruses were generated from their synthetic
complementary DNA using the human RNA polymerase I reverse genetics system. Secondly, the major immunogenic capsid
protein (VP1) of EV71-Fuyang (subgenogroup C4) was displayed on the surface of recombinant baculovirus Bac-Pie1-gp64-
VP1 as gp64 fusion protein under a novel White Spot Syndrome Virus (WSSV) immediate early ie1 promoter. Baculovirus
expressed VP1 was able to maintain its structural and antigenic conformity as indicated by immunofluorescence assay and
western blot analysis. Interestingly, our results with confocal microscopy revealed that VP1 was able to localize on the
plasma membrane of insect cells infected with recombinant baculovirus. In addition, we demonstrated with transmission
electron microscopy that baculovirus successfully acquired VP1 from the insect cell membrane via the budding process.
After two immunizations in mice, Bac-Pie1-gp64-VP1 elicited neutralization antibody titer of 1:64 against EV71
(subgenogroup C4) in an in vitro neutralization assay. Furthermore, the antisera showed high cross-neutralization activities
against all 11 subgenogroup EV71 strains.
Conclusion: Our results illustrated that Bac-Pie1-gp64-VP1 retained native epitopes of VP1 and acted as an effective EV71
vaccine candidate which would enable rapid production without any biosafety concerns.
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Introduction
Human enterovirus 71 (EV71) is a common cause of hand-foot-
and mouth disease (HFMD) in young children below 6 years old
[1–6]. EV71 infections usually are mild, but occasionally lead to
severe diseases such as aseptic meningitis, poliomyelitis-like
paralysis, and possibly fatal encephalitis [7]. Outbreaks of EV71
with significant morbidity and mortality have been reported
worldwide and especially in the Asia-Pacific region. EV71 is
associated with fatal cases of HFMD during the large outbreaks in
Malaysia in 1997 [2], Taiwan in 1998, 2000 and 2001 [3–4],
Australia in 1999 [6], Singapore in 2000 [6,8] and China (2008).
From 1999 to 2010, HFMD outbreaks caused by EV71 have
affected more than 500,000 children and resulted in more than
200 deaths in China. In fact, after the eradication of poliovirus,
EV71 is now regarded as the most important neurotropic
enterovirus and a threat to global public health [8–11].
Like poliovirus, EV71 is a small, nonenveloped, positive-stranded
RNA viral pathogen within the Picornaviridae family. The genome of
EV71 contains a single large coding region flanked by 59-a n d3 9-
untranslated regions (59-a n d3 9- UTR). The coding region is
translated to a single polypeptide, which is then processed by viral
proteasesto yield nonstructural proteins and 4 capsidproteins: VP1,
VP2, VP3 and VP4 assembled as pentameric subunits [12]. The
VP1 protein is exposed on the surface of virion and usually targeted
by host neutralizing antibodies. Therefore, the VP1 gene is thought
to play an important role in viral pathogenesis and virulence [13].
Based on the VP1 gene sequence, EV71 is divided into three major
genogroups (denoted A, B and C), and various subgenogroups
within genogroups B (B1 to B5) and C (C1 to C5) [14].
Currently, there is no commercial antiviral therapy or vaccine
against EV71 infection. The prevention and control of EV71 has
simply relied on public health surveillance and quarantine.
Because VP1 is involved in the recognition of EV71 receptors
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17], the usefulness of VP1 to generate a subunit vaccine has
recently been highlighted. Several vaccine candidates based on
VP1, including synthetic peptides containing VP1 linear neutral-
izing epitope [20,21], recombinant VP1 produced in milk samples
of transgenic mice [17] or E. coli [17,18], bacterially or virally
expressed VP1 [15,19] and VP1 DNA vaccine [17,22], are
immunogenic and show good immune response in vaccinated
mice. However, over expression of these proteins has been
associated with poor solubility, improper folding and the need of
expensive purification methods.
Baculovirus, Autographa californica nuclear polyhedrosis virus
(AcNPV), was initially used as a biological pesticide, but is
nowadays best known for its value as a eukaryotic expression
vector and a potential vaccine delivery platform [23]. The
baculovirus surface display method is based on the expression of
foreign proteins fused to the baculovirus gp64 protein [24]. Gp64
is a 64 kDa envelope glycoprotein which is incorporated into viral
particles as they bud from the surface of infected cells and it
probably mediates penetration of viruses into host cells by
adsorptive endocytosis. Gp64 comprises an N-terminal signal
peptide (SP) and a mature domain (MD) that includes the
transmembrane domain (TM) and cytoplasmic domain (CTD)
[25,26]. The gp64 fusion protein consists of a foreign peptide
inserted between SP and mature domain. The fusion protein is
translocated to the plasma membrane after expression and
incorporated into the baculovirus envelope along with native
gp64. This method has been utilized to develop recombinant
baculoviruses as a potential vaccine delivery platform [27–29].
Foreign proteins that are expressed in the baculovirus system
usually are under the control of the conventional baculovirus
polyhedrin promoter which acts strongly in Sf9 cell but is less
active in mammalian cells. A novel White Spot Syndrome Virus
(WSSV) immediate early ie1 promoter was found to be active in
both Sf9 cell and mammalian cells, such as Vero, BHK-21, 293T
and human colorectal carcinoma (HCT 116) cells [30,31].
Therefore, the ie1 promoter allows the expression of foreign
proteins not only in Sf9 cell but also mammalian cells after
transduction of the baculoviral genome into the host.
In this study, we generated an infectious clone of the C4 strain
EV71-Fuyang, which led to an EV71 outbreak in Fuyang city of
China in 2008 [32]. Virus was produced from its synthetic
genomic complementary DNA (cDNA) using the human RNA
polymerase I reverse genetics system [33–36]. We also successfully
generated chimeric EV71 strains with the EV71-Fuyang backbone
and VP1 genes from other EV71 subgenogroups. Since the VP1
protein is the most important immunogen eliciting anti-EV71
antibodies and because the recombinant baculovirus is a
promising vaccine vehicle, we constructed two recombinant
baculoviruses Bac-Piel-gp61-VP1 and Bac-Pph-gp64-VP1. Both
expressed the EV71-VP1 (of Fuyang strain) fused with the mature
domain of baculovirus gp64 protein under WSSV ie1 promoter
(Pie1) and conventional baculovirus polyhedrin promoter (Pph),
respectively. We demonstrated that the recombinant baculoviruses
successfully displayed VP1 antigen of EV71 on their viral surface
and that they induced humoral immune responses against EV71
infection upon in vivo immunization in mice.
Materials and Methods
Generation of EV71 virus from its synthetic
complementary DNA
EV71 strain Fuyang/02/08 (EU703813, subgenogroup C4) was
generated from its synthetic genomic cDNA using the human RNA
polymerase I system. Briefly, the whole cDNA of the virus (7405 bp)
with a poly(A) tail containing 25 adenosines was chemically
synthesized (Genscript, USA) as two fragments (F1 and F2,
Figure 1) with an overlapping region at the internal Aar I restriction
enzyme site. Human RNA polymerase I (hRNA pol1) promoter
(225 bp) was amplified using primers hRNA-pol1-f and hRNA-pol1-r
Figure 1. Generation of infectious EV71 from synthetic cDNA by the human RNA polymerase I reverse genetics system. (A) Illustration
of cDNA of EV71-Fuyang (EU703813). P: Human RNA I polymerase promoter (225 bp); An: ploy-A tail with 25 adenosines; mT: murine terminator
(33 bp). (B) RD cells were directly transfected by plasmid pJET-EV71-fuyang and the VP1 antigen was detected by guinea pig anti-VP1 sera 3 days
post-transfection. The recovered EV71 was infectious when passged in RD cells (P1= Passage 1; P2= Passage 2).
doi:10.1371/journal.pone.0021757.g001
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the reverse genetic system [34]. The F1 was amplified with primers
F1-f and F1-r using PfuUltra high-fidelity DNA polymerase
(Stratagene), and then joined together with human RNA polymerase
I promoter by overlapping PCR, resulting in the product hRNA-
pol1-F1. Meanwhile, F2 was cloned with primers F2-f and F2-r
containing a murine terminator sequence and named F2-mTer. The
hRNA-pol1-F1 and F2-mTer were digested by Aar I (Fermentas),
and ligated with pJET1.2/blunt cloning vector (Fermentas) in a triple
ligation reaction. The positive recombinant plasmid was cloned in
XL1-blue E. coli and named pJET-EV71-Fuyang.
For chimeric EV71 viruses, VP1 genes from subgenogroups B1,
B3 and C3 (Table 1) flanked with EV71-Fuyang gene fragments
(2418-2437 bp at 59 end and 3329-3450 bp at 39 end) were
synthesized (Genscript) and amplified with primers EV71-f(2418)
and EV71-r(3450). Each of these VP1 genes was then joined with
the EV71-Fuyang gene fragment (1400-2438 bp, amplified using
primers EV71-f(1400) and EV71-r(2438)) by overlapping PCR
using primers EV71-f(1400) and EV71-r(3450). After digestion
with NarI and NruI (NEB), the PCR products containing
heterologous VP1 genes were inserted into pJET-EV71-Fuyang
replacing the original VP1 gene of pJET-EV71-Fuyang. These
chimeric EV71 constructs were named pJET-EV71-Fuyang (VP1-
B1), pJET-EV71-Fuyang(VP1-B3), and pJET-EV71-Fuyang(VP1-
C3) and sequences were confirmed by DNA sequencing.
The purified pJET-EV71-Fuyang and 3 chimeric EV71
constructs were transfected into human rhabdomyosarcoma
(RD) cells with Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s protocol. The transfected cells were lysed after 4
days by 3 freeze-thaw cycles and the supernatant containing
viruses was collected for further infection. After 2 passages in RD
cells, the generated viruses were harvested and detected with
guinea pig anti-VP1 sera (prepared by immunizing with purified
His-tagged VP1 expressed in E. coli) in IFA (described below).
EV71-Fuyang was used as homologous strain and its VP1 gene
was used to construct the recombinant baculoviruses. Eight other
wild type EV71 strains (Table 1) kindly provided by Professor
Vincent T. K. Chow (National University of Singapore) and 3
chimeric EV71 strains, i.e. EV71-Fuyang(VP1-B1), EV71-
Fuyang(VP1-B3), and EV71-Fuyang(VP1-C3) were used as
heterologous strains in the neutralization assay. All EV71 viruses
were grown in RD cells in Dulbecco modified Eagle medium
(DMEM) (Gibco, USA) supplemented with 10% fetal bovine
serum (FBS), 6 g/l sodium bicarbonate and antibiotics at 37uC
with 5% carbon dioxide and humidity.
Purification and inactivation of EV71 virus
The RD cells were infected by the reverse genetically
engineered EV71 virus (EU703813) at a multiplicity of infection
(MOI) of 0.1. Once the cells showed cytopathic effect (CPE), they
were harvested and completely lysed by 3 freeze/thaw cycles.
Cellular debris was removed by centrifugation at 5,000 x g for
30 min. The virus was purified by precipitation with 7%
polyethylene glycol 8000 (PEG 8000) and centrifugation through
30% sucrose cushion at 30,000 g for 4 h. The 50% tissue culture
infective dose (TCID50) was determined in RD cells using the
Reed and Muench formula [37]. The purified virus was heat-
inactivated at 56 for 30 min, and the amount of virion protein was
quantified by the Bradford assay (Bio-Rad Laboratories, USA).
Construction of recombinant Bacmid DNA for
baculovirus surface display of VP1
The gp64 mature domain (MD) was amplified from wild-type
bacmid DNA using primers gp64-MD-f and gp64-MD-r. The
VP1 gene was amplified from genomic RNA of EV71 by RT-PCR
using primers VP1-f and VP1-r. The gp64-VP1 gene was
amplified from an equal molar mixture of purified gp64 MD
gene with purified VP1 gene by overlapping PCR using primers
gp64-SP-f and gp64-MD-R. The PCR product gp64-VP1 was
purified and digested by RsrII and HindIII, then inserted into pFast
HT A vector. The positive plasmids were verified by DNA
sequencing and named pFast-Pph-gp64-VP1. In addition, the
Table 1. Primers used for construction of recombinant plasmids.
Primer Sequence (59R39)
hRNA-pol1-f 59-GCCCCTGCGTGTGGCACG-39
hRNA-pol1-r GGTGCAACCCACAGGCTGTTTTAAAATAACCCGGCGGCCCAAAATGC
F1-f TTAAAACAGCCTGTGGGTTGC
F1-r GTAAGCACTCGCAGGTGA CATGAATG
F2-f CATTCATGTCACCTGCGAGTGCTTAC
F2-r GCCCGGAGTACTGGTCGACCTCCGAAGTTGGGGGGGTTTTTTTTTTTTTTTTTTTTTTTTTGCTATTCTGG
EV71-f(2417) CTGCAGACGGGCATCATCCAG
EV71-r(3450) AGTAAGTCGCGAGAGCTGTC
EV71-f(1400) ACTCAACCCGGCGCCGATG
EV71-r(2437) CTGGATGATGCCCGTCTGCAG
gp64-MD-f GAGCACTGCAACGCGCAAATG
gp64-MD-r GGGTAAGCTTTTAATATTGTCTATTACGGTTTCTAATCATAC
VP1-f GCATTCTGCCTTTGCGGATCTGCAGGGAGATAGGGTGGCAGATG
VP1-r CATTTGCGCGTTGCAGTGCTCAAGAGTGGTGATCGCTGTG
gp64-SP-f TCTCGGTCCGACCATGGTAAGCGCTATTGTTTTATATGTGCTTTTGGCGGCGGCGGCGCATTCTGCCTTTGCGGAT
WSSVie1-f CCTACGTATCAATTTTATGTGGCTAATGGAGA
WSSVie1-r CGCGTCGACCTTGAGTGGAGAGAGAGCTAGTTATAA
doi:10.1371/journal.pone.0021757.t001
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removed by AccI and RsrII enzymes and replaced by the ie1
promoter of White Spot Syndrome Virus (WSSV), and the new
plasmid was named pFast-Pie1-gp64-VP1. The ie1 promoter was
amplified from WSSV genomic DNA using primers WSSVie1-f
and WSSVie1-r as previously described [31].
Competent DH10Bac E. coli cells were then transformed with the
recombinant plasmids pFast-Pph-gp64-VP1 and pFast-Pie1-gp64-
VP1. After selecting colonies through two rounds of blue/white
selection and PCR with M13 forward and reverse primers,
recombinant bacmid DNA was isolated from white colonies
according to the standard procedure (Bac-to-Bac system, Invitrogen).
Generation and purification of recombinant
baculoviruses
Baculovirus was propagated in Spodoptera frugiperda Sf9 III cell
lines (ATCC) which were grown at 27uC in serum-free medium
SF-900 III (Invitrogen). Procedures for the generation of
recombinant baculovirus were carried out according to the
manufacturer’s manual (Invitrogen). Briefly, 10
6 Sf9-III cells were
cultured in 6-well plates for 1 h. After attachment, 4 mgo f
recombinant bacmid DNA Bac-Pph-gp64-VP1 or Bac-Pie1-gp64-
VP1 was mixed with 10 ml Cellfectin II (Invitrogen) in Grace’s
insect medium, and then transfected into the Sf9 III cells.
Transfected cells were incubated for 5 h at 27uC and the
transfection medium was then replaced with fresh medium SF-
900 III. After incubation for 72 h at 27uC, the supernatant
containing recombinant viruses was used for infecting more fresh
Sf9 cells. For large scale viral production, Sf9-III cells were
infected at 0.2 MOI in suspension cultures of 2610
6 cells/ml. Four
days post infection, the supernatant was collected and the
recombinant viruses were purified by two rounds of sucrose
gradient ultracentrifugation following standard protocols [38].
The purified recombinant baculoviruses were resuspended in PBS
and titered by plaque assay.
Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and Western blot analysis
The purified baculoviruses and heat-inactivated EV71 were
subjected to 8% SDS-PAGE and transferred to nitrocellulose
membranes. Two primary antibodies, mouse anti-gp64 monoclo-
nal antibody (1:10,000, Merk) and guinea pig anti-VP1 serum
(1:2000), were used to detect gp64 fusion proteins in Western blots.
The secondary antibodies were horseradish peroxidase (HRP)
conjugated goat anti-mouse IgG antibodies (1:3000, DAKO) or
HRP conjugated rabbit anti-guinea pig IgG antobodies (1:3000,
DAKO). The protein bands were visualized by the Amersham
ECL Plus Western Blotting Detection Reagents (GE Healthcare).
Immunofluorescence assay and confocal microscopy to
detect expression of recombinant VP1 protein in insect
cells
The Sf-9 cells were cultured on glass bottom microwell dishes
(MatTek Corporation) to 50% confluency and infected with an
MOI of 0.2. Three days after infection, the cells were fixed by
methanol/acetone (1:1) for 10 min at 220uC, rinsed with PBS-T,
and blocked with 1% bovine serum albumin for 30 min at 37uC.
The cells were incubated with the primary anti-VP1 sera (1:2000)
for 1 h at room temperature, followed by three PBS-T washes.
The cells were then incubated with the secondary fluorescein
isothiocyanate (FITC)-conjugated goat anti-guinea pig IgG
monoclonal antibody (1:100) for 1 h at room temperature,
followed by DAPI (2, 4-diamidino-2-phenylindole) staining at a
concentration of 1 mg/ml for 15 min at room temperature and
three PBS-T washes. The negative control cells were treated
similarly. The FITC signal was detected with an inverted
fluorescence microscope (Olympus), and the images were captured
by a digital imaging system (Nikon). The cellular localization of
recombinant VP1 proteins in Sf9 cells was visualized using a
confocal microscope (LSM 510, Zeiss, USA).
Immunogold Electron Microscopy
Carbon-coated grids were floated on purified baculovirus
solution for 30 min, blocked, washed with PBS three times for
5 min, and then exposed to anti-VP1 sera (1:1000) for 30 min.
After two PBS washes, the grids were exposed to anti-guinea pig
IgG conjugated with 10-nm gold particles (1:50) (Sigma) for
30 min. After three more PBS washes, the grids were stained with
2% phosphotungstic acid (Sigma) and examined under the
transmission electron microscope JEM-1230 (Jeol).
Mice Immunization
Five groups of mice, each including six 4-week old female
BALB/c mice, were immunized subcutaneously twice on day 0
with 100 ml solution containing 20 mg inactivated EV71, 10
8 pfu
purified Bac-Pph-gp64-VP1, 10
8 pfu purified Bac-Pie1-gp64-VP1,
10
8 pfu purified wild-type baculovirus Bac-wt, or RD cell lysate,
respectively, with Freund complete adjuvant (Sigma). On day 21,
the mice were boosted with the same antigens with Freund
incomplete adjuvant (Sigma). Inactivated EV71 was used as
positive control, while wild type baculovirus Bac-wt and RD cell
lysate served as negative control. 200 ml of blood samples were
taken from every mouse by facial bleeding on days 14, 28 and 42,
and final bleeding was done on day 56. The sera were harvested
for the ELISA and the neutralization titer test.
All animal experiments were carried out in accordance with the
Guides for Animal Experiments of the National Institute of
Infectious Diseases (NIID), and experimental protocols were
reviewed and approved by Institutional Animal Care and Use
Committee of the Temasek Life Sciences Laboratory (Project
Approval no. TLL-11-002), National University of Singapore,
Singapore.
ELISA for detection of anti-EV71 antibodies
The levels of specific IgG against EV71 in sera of immunized
mice were determined by indirect enzyme-linked immunosorbent
assay (iELISA). Briefly, U bottom 96-well microtiter plates were
coated with 100 mlo f1 0
6 TCID50 inactivated EV71-Fuyang
viruses in carbonate-coating buffer (15 mM Na2CO3,3 5 m M
NaHCO3, pH 9.8). The plates were incubated at 4uC overnight
followed by incubation with 1% BSA in PBS containing 0.05%
tween20 (PBS-T) for 1 h at room temperature to prevent non-
specific binding. 1000 times diluted sera from immunized mice
were then added to plates in duplicates and incubated for 1.5 h at
room temperature. After three times washing with PBS-T,
horseradish peroxidase (HRP) conjugated goat anti-mouse IgG
antibody (1:2000, DAKO) was added into each well. The reaction
was developed by 100 ml TMB substrate (3, 39,5 ,5 9-etramethyl-
benzidine) for 10 min incubation in a dark room, and then
terminated by adding 50 ml2 MH 2SO4. The optical densities at
450 nm were determined with a microplate absorbance reader
(Sunrise, Tecan).
Virus Neutralization Titer (NT) Assay
The presence of neutralizing antibodies against EV71 was
assayed by a microneutralization test in vitro. First, the mouse sera
Baculovirus Surface Display of Enterovirus 71 VP1
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25 ml of serial two-fold dilutions of serum was mixed with 25 mlo f
100 TCID50 of virus, and incubated at 37uC for 2 h to neutralize
infectious viruses. The mixtures were then transferred to 96-well
plates with more than 90% confluent monolayers of RD cells in
DMEM containing 5% FBS. After incubation for 5 days at 37uC,
the neutralizing antibody titer was read as the highest dilution of
serum that completely inhibited virus growth. The experiment was
done in duplicates and the average neutralization titer was
recorded.
Results
Generation of infectious EV71 virus from synthetic cDNA
using the human RNA polymerase I system
The plasmid pJET-EV71-Fuyang containing the genomic
cDNA of EV71 under the high-fidelity hRNA pol1 promoter
was successfully generated according to the method described
(Figure 1A). After direct transfection into RD cell, the genomic
cDNA of EV71 was transcribed into genomic RNA of EV71 and
translated into EV71 polypeptides. The polypeptides were then
self-cleaved into functional proteins which successively replicated
their genomic RNA and assembled into infectious EV71 virus
particles. The viral protein VP1 was detected by guinea pig anti-
VP1 sera after transfection of pJET-EV71-Fuyang and two serial
passages (Figure 1B). It was obvious that the virus could be
recovered from RD cells and was infectious due to the increasing
amount of VP1 in progressive passages as seen by IFA. The titer of
in vitro generated EV71-Fuyang increased with serial passages, and
reached a maximum of 3610
8 TCID50/ml (data not shown). The
in vitro generated EV71 viruses caused similar CPE in RD cells as
other wild-type EV71 viruses. Furthermore, the sera collected
from mice immunized with the in vitro generated EV71-Fuyang
neutralized the wild-type EV71 strains from different subge-
nogroups which demonstrated that the virus retained immuno-
genic sites. For 3 chimeric EV71 viruses EV71-Fuyang(VP1-B1),
EV71-Fuyang(VP1-B3) and EV71-Fuyang(VP1-C3), the same IFA
results and virus titers were observed (data not shown).
Confirmation of gp64-VP1 expression in insect cells
The correctness of pFast-Pph-gp64-VP1 and pFast-Pie1-gp64-
VP1 was confirmed by DNA sequencing. After transformation
into DH10Bac, the recombinant baculoviral genomic DNA Bac-
Pph-gp64-VP1 and Bac-Pie1-gp64-VP1 was successfully selected
and purified. Sf9 III cells were then transfected and the
recombinant baculoviruses expressing gp64-VP1 protein were
generated. Our strategy predicted that the gp64 SP would
facilitate the transport of the gp64-VP1 to the plasma membrane
and be cleaved, thus exposing VP1 on the outer surface of Sf9
cells. Furthermore, the mature domain of gp64 would enable the
gp64-VP1 to anchor in the plasma membrane, and then mediate
the incorporation of gp64-VP1 into the baculovirus envelope
(Figure 2).
To examine the expression of the fusion protein gp64-VP1 in
Sf9 cells, the cells were infected by the recombinant baculoviruses
Bac-Pph-gp64-VP1, Bac-Pie1-gp64-VP1 or Bac-wt which were
collected from the transfection supernatant. Four days post-
infection, the cells were fixed by methanol/acetone and expression
Figure 2. Construction of plasmids for gp64-VP1 expression by baculovirus. The VP1 gene was incorporated between gp64 signal peptide
and gp64 mature domain by overlapping PCR. The recombinant gene gp64-VP1 was then inserted into pFastBac HT A. The resultant plasmids were
designated pFast-Pph-gp64-VP1. The polyhedrin promoter (Pph) was later replaced by WSSV ie1 promoter which is active in both Sf9 and
mammalian cells. Like gp64 protein, the recombinant protein gp64-VP1 should be transported to the surface of the infected Sf9 cells, and
incorporated into the surface of recombinant baculoviruses.
doi:10.1371/journal.pone.0021757.g002
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in IFA. In contrast, no signal was detected by anti-VP1 sera in the
negative controls (Bac-wt infected Sf9 cells and mock infected Sf9
cells) (Figure 3).
To determine whether the recombinant gp64-VP1 was properly
translocated to the cell surface, the cells were cultured on glass
bottom microwell dishes infected with recombinant baculoviruses
at an MOI of 0.2, and subjected to IFA at 3 days post-infection.
The infected cells were observed under a confocal microscope. As
shown in Figure 4, gp64-VP1 was detected in Sf9 cells infected by
Bac-Pie1-gp64-VP1 (cells infected by Bac-Pph-gp64-VP1 showed
the same results, data not shown), but not in non-infected cells
with guinea pig anti-VP1 serum. The gp64-VP1 protein mainly
localized within the plasma membrane of Sf9 cells, demonstrating
the successful anchoring of gp64-VP1 on the surface of the
infected cells.
Display of gp64-VP1 proteins on the baculovirus
envelope
To confirm whether the gp64-VP1 was successfully displayed on
the baculovirusenvelope,recombinantbaculovirusesBac-Pph-gp64-
VP1 and Bac-Pie1-gp64-VP1were purified by two rounds of sucrose
gradient ultracentrifugation. Finally, the recombinant baculoviruses
were resuspended in PBS at a concentration of 10
8 pfu/100 ml.
Incorporation of recombinant proteins into the baculovirus particles
was analyzed by Western blotting.The gp64-VP1 fusion protein was
detected by both anti-gp64 mAb and anti-VP1, at a molecular
weight of about 98 kDa (Figure 5). Furthermore, the recombinant
gp64-VP1 on the baculovirus envelope was visualized by immuno-
gold electron microscopy using primary anti-VP1 sera and
secondary antibodies conjugated to 10 nm gold particles. In
Figure 6, gold particles on the surface of baculoviruses Bac-Pph-
gp64-VP1 and Bac-Pie1-gp64-VP1 indicated the incorporation of
Figure 4. Anchoring of gp64-VP1 on the surface of the infected
Sf9 cells. The cells were cultured on sterile glass bottom microwell
dishes, infected with baculovirus Bac-Pie1-gp64-VP1 at a MOI of 0.2, and
subjected to immunofluorescence staining followed by confocal
microscopy 3 days post-infection. The blue channel showed the stained
nuclei of Sf 9 cells, whereas the green channel showed the localization
of gp64-VP1 fusion protein on the plasma membrane of infected cells.
In contrast, the uninfected cells were not detected by anti-VP1 sera.
doi:10.1371/journal.pone.0021757.g004
Figure 3. Expression of gp64-VP1 proteins in Sf9 cells. Fresh Sf9 cells were infected by the recombinant baculoviruses Bac-Pph-gp64-VP1 and
Bac-Pie1-gp64-VP1 as well as wild-type Baculovirus Bac-wt. Four days post-infection, all infected cells showed distinctive CPE, while mock cells did
not. Cells were fixed and incubated with guinea pig anti-VP1 sera followed by FITC-conjugated anti-guinea pig IgG antibodies for IFA. The cells
infected by baculovirus Bac-Pph-gp64-VP1 or Bac-Pie1-gp64-VP1 showed positive signals, while no staining was observed in cells infected by wild-
type baculovirus or mock-infected cells.
doi:10.1371/journal.pone.0021757.g003
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gold particles were observed on the surface of wild type baculovirus
Bac-wt.
EV71-specific antibodies levels in sera of immunized mice
We proceeded to explore whether the in vitro generated EV71-
Fuyang and the gp64-VP1 displayed on the baculovirus envelope
could serve as immunogens in vivo. Total IgG antibody levels in
antisera were assayed by indirect ELISA by coating whole
inactivated EV71 virus onto U bottom 96-well plates. The
antisera from mice immunized with Bac-wt, or RD cell lysate
were used as negative controls. The mice immunized with purified
Bac-Pph-gp64-VP1 and Bac-Pie1-gp64-VP1 generated an ade-
quate antibody response against EV71. Meanwhile, the inactivat-
ed EV71-Fuyang elicited the highest EV71 antibody levels. In
contrast, injection with Bac-wt or RD cell lysate did not elicit
Figure 6. Immunogold electron micrographs of purified recombinant baculoviruses. gp64-VP1 was detected by guinea pig anti-VP1 sera
as the primary antibody and anti-guinea pig IgG conjugated with 10 nm gold particles as the secondary antibody (magnification at 200,000x). Gold
particles attached to the surface of heads of recombinant baculoviruses Bac-Pie1-gp64-VP1 and Bac-Pph-gp64-VP1 expressing gp64-VP1. In contrast,
no gold particles were detected on the surface of wild-type baculoviruses Bac-wt.
doi:10.1371/journal.pone.0021757.g006
Figure 5. Confirmation of gp64-VP1 expression in purified baculoviruses by Western blotting. Purified baculoviruses Bac-Pph-gp64-VP1,
Bac-Pie1-gp64-VP1, Bac-wt and inactivated EV71 were separated on 8% SDS-PAGE gel and transferred onto nitrocellulose membranes. Anti-gp64
monoclonal antibodies (mAbs) and guinea pig anti-VP1 sera were used to detect gp64 and VP1 antigen, respectively.
doi:10.1371/journal.pone.0021757.g005
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ELISA (Figure 7). The level of specific antibodies against EV71
reached a maximum at 28 days post-immunization and remained
at a high level until 56 days post-immunization. The EV71
antibody level elicited by baculovirus Bac-Pie1-gp64-VP1 was
slightly higher than that of Bac-Pph-gp64-VP1.
Neutralization titers of sera of immunized mice
The antisera were analyzed in an in vitro microneutralization
assay to determine their ability to neutralize live EV71-Fuyang
replication in RD cells. Consistent with the negligible IgG titer, the
neutralization titers induced by the Bac-wt and RD cell lysate
antisera were barely detectable (,1:8). In a time-scale study
(Figure 8), the inactivated EV71-Fuyang, Bac-Pph-gp64-VP1, and
Bac-Pie1-gp64-VP1 antisera resulted in a neutralization titer profile
similar to the antibody titer profile, with neutralization titers
culminating at 28 days and persisting for at least 56 days. After two
immunizations with adjuvant, the inactivated EV71 virus induced a
neutralization titer of 1:128 against EV71 replication in RD cells,
while the baculovirus Bac-Pie1-gp64-VP1 and Bac-Pph-gp64-VP1
induced neutralization titer of 1:64 and 1:32, respectively.
These antisera against homologous VP1 of the Fuyang strain
exhibited cross-neutralization activities against wild-type EV71
strains from subgenogroups A, B2, B4, B5, C1, C2, C4 and C5
(Table 2). The data showed that Bac-Pie1-gp64-VP1 induced
higher neutralization antibody titers than Bac-Pph-gp64-VP1 and
had a greater potential to be effective against heterologus EV71
subgenogroups. The neutralization titer of anti Bac-Pie1-gp64-
VP1 serum was around 1:64 against EV71 genogroup C strains
and 1:32 against genogroup B EV71 strains (Figure 9). Therefore,
baculovirus-surface displayed VP1 successfully retained antigenic
sites of EV71, could elicit good neutralizing antibody response and
may serve as a candidate vaccine for EV71.
Discussion
In recent years, reverse-genetics systems for the generation of
RNA viruses from their cDNA have proven to be of great value for
virus research and vaccine development [33,35,36,39]. A previous
study has described EV71 recovery methods using infectious RNA
which was transcribed in vitro from full length cDNA using T7
RNA polymerase [39]. The drawbacks to this method include
their complexity, expense, and laboriousness. Additionally, any
mutations introduced by proof-reading deficient T7 RNA
polymerases used to generate viruses may lead to less viable
infectious particles. In this study, we describe an accurate in vitro
generation of EV71-Fuyang strain in cell culture from its synthetic
cDNA by utilizing a eukaryotic cellular RNA polymerase: hRNA
pol1. After direct transfection into RD cells, the EV71 cDNA
under the hRNA pol1 promoter was transcribed into EV71
genomic RNA by hRNA pol1 inside the cells. This method
abolishes the need for troublesome in vitro RNA transcription and
will be useful for EV71 vaccine research.
Baculovirus surface display is extensively used for vaccine
production [40,41]. In previous studies, we have demonstrated the
use of baculovirus surface display technology for candidate vaccine
development against highly pathogenic avian influenza [31,42,43],
and White spot syndrome virus [29]. In the present study, we have
shown that baculovirus displaying gp64-VP1 is a candidate
vaccine against EV71. A recombinant baculovirus with the
immediate-early promoter 1 of WSSV (Bac-Pie1-gp64-VP1) or
conventional polyhedrin promoter (Bac-Pph-gp64-VP1) was
constructed. Importantly, WSSV ie1 promoter facilitates high-
level expression of target protein in insect cells [44]. The nature of
ie1 as an immediate-early promoter supports protein expression at
the early phase of the baculoviral life cycle, resulting in an
enhanced display of the target protein on the baculovirus envelope
and it also facilitates efficient transduction of mammalian cells
[44,31]. For the purpose of displaying foreign proteins on the
surface of baculovirus particles, gp64 serves as a fusion partner
that gets incorporated into the cell membrane and into budded
virions together with a chosen target protein [40]. Our results with
confocal microscopy revealed that VP1 was able to localize to the
plasma membrane of insect cells infected with recombinant
baculovirus. In addition, we demonstrated with transmission
Figure 7. Measurement of EV71-specific IgG antibody levels by indirect ELISA. Five groups of mice, each including 6 female BALB/c mice,
were immunized subcutaneously twice at days 0 and 21 with 100 ml solution containing 20 mg of inactivated EV71, 10
8 pfu of purified Bac-Pph-gp64-
VP1, 10
8 pfu of purified Bac-Pie1-gp64-VP1, 10
8 pfu of purified wild-type baculovirus Bac-wt and RD cell lysate, respectively, mixed with 100 ml
adjuvant. Each column represents the arithmetic mean value (n6) 6SD (*p,0.001; **p,0.01).
doi:10.1371/journal.pone.0021757.g007
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from the insect cell membrane via the budding process.
We presumed that VP1 displayed on the baculovirus surface
should have been presented in its native form. Hence, we
attempted to use Bac-Pie1-gp64-VP1 as a vaccine candidate
against EV71 infection. The Bac-Pie1-gp64-VP1 was able to
induce systemic immune responses in the vaccinated mice, as
indicated by the high level of VP1-specific IgG antibodies in
ELISA. In vitro microneutrolization assay revealed that Bac-Pie1-
gp64-VP1 induced a neutralization titre of 1:64 against homolo-
gous EV71 C4 strain, which is comparable to the neutralization
titre induced by inactivated EV71. The EV71 neutralizing
antibody level elicited by baculovirus Bac-Pie1-gp64-VP1 was
slightly higher than that of Bac-Pph-gp64-VP1. This may be due
to the increased activity of WSSV ie1 promoter inside the mouse
cells leading to the expression of extra gp64-VP1. In our previous
study, we have reported that baculovirus displaying influenza
hemagglutinin under the control of ie1 promoter can efficiently
transduce intestinal epithelial cells in vivo [31]. However, a more
detailed study is required to address the role of different promoters
in the efficacy of baculovirus surface displayed vaccine. One
important issue is whether VP1 subunit vaccines directed against
one EV71 genetic subgroup will provide cross-protection against
all others since available data are contradictory [45,46]. The
circulating EV71 subgenogroups are changing rapidly, and
knowing whether immunity to one subgenogroup confers
protection against others is crucial, as it is preferable to have a
vaccine that can broadly protect from different subgenogroups of
EV71. We demonstrated that antibodies induced by the Bac-Pie1-
gp64-VP1 vaccine of the C4 subgenogroup can neutralize other
heterologous subgenogroups with 2 to 4 fold difference. This
finding agrees with those of other studies showing that hyperim-
mune animal sera as well as human patient sera derived from one
particular subgenogroup exhibit broad neutralizing activity against
other subgenogroups [46–49]. These observations show the broad
efficacy of the Bac-Pie1-gp64-VP1 vaccine against EV71. One
limitation in EV71 vaccine development is the lack of a
Table 2. List of the EV71 strains used in this study.
Virus strain Genotype Origin GenBank Ref.
BrCr A USA U22521.1
EV71-Fuyang(VP1-B1)* B1 USA AF135901
7432/MS/87 B2 USA U22522.1
EV71-Fuyang(VP1-B3)* B3 Australia AF376093
8565/SIN/000009 B4 Singapore AF316321
NUH0083/SIN/08 B5 Singapore FJ461781
Y90-3761 C1 Japan AB433864
1585-Yamagata-01 C2 Japan AB177812
EV71-Fuyang(VP1-C3)* C3 South Korea AY125973
75-Yamagata-03 C4 Japan AB177813
EV71-Fuynag/02/2008* C4 China EU703813
3437/SIN/06 C5 Singapore GU222654
*Viruses were generated from its synthetic cDNA using human RNA polymerase
I system.
doi:10.1371/journal.pone.0021757.t002
Figure 8. Neutralization titers of the sera of immunized mice. Inactivated EV71 virus, purified baculoviruses Bac-Pph-gp64-VP1 and Bac-Pie1-
gp64-VP1 were used in immunization. Wild-type baculovirus (Bac-wt) and RD cell lysate were used as negative controls. Each column represents the
arithmetic mean value (n6) 6SD (*p,0.001; **p,0.05). For inactivated EV71, the neutralization titer against EV71 replication in RD cells readed 1:128,
while our baculovirus surface displayed VP1 elicited neutralization titers of 1:32 to 1:64.
doi:10.1371/journal.pone.0021757.g008
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infection. Although suckling mice are susceptible, by the time
immunity develops after inoculation, the animals have matured
and become resistant to infection. Owing to unavailability of a
suitable animal model at our facility, viral challenge experiments
were not performed. However, the high neutralization titers of our
antisera in vitro indicates that they should offer passive protection
to suckling mice. Based on the literature of EV71 vaccine studies,
antisera with neutralization titers of 1:64 were able to protect
suckling mice in a passive protection study [18,20]. As the
neutralization titers of our antisera are in the same range with
those previously described, we would expect an equally good
passive protection.
No treatment against EV71 exists, but by analogy with
poliomyelitis, vaccination probably offers the best option for
EV71 control. Various types of vaccines are being investigated,
including inactivated whole-virus, live attenuated, virus-like
particle (VLP), and DNA vaccines. All vaccine prototypes are in
the early stages of development, with the most advanced
undergoing preclinical trials in mice and non-human primates
[50]. These candidates include an avirulent EV71 vaccine [51], an
EV71-like particle vaccine [52], a DNA vaccine [17,22] and a
recombinant VP1 protein vaccine derived from milk of
engineered transgenic mice to produce capsid proteinVP1 [19].
All these vaccines elicited good immune responses in vaccinated
mice. However, overexpression of these proteins has been
associated with poor solubility, improper folding and the need of
expensive purification methods, while live attenuated EV71
vaccine harbors a potential risk of reversion. As reported in
candidate EV71 vaccine strain EV71 (S1-3), the vaccine strain
itself caused mild neurological symptoms (tremor) in cynomolgus
monkeys and entered the spinal cord, which indicated that further
work on attenuation is needed [53]. Among the various vaccine
candidates, inactivated whole virus vaccines are in some ways most
ready to develop further, because the principles of vaccines based
on inactive whole virus are well-established. However, inactivation
usually destroys epitopes and reduces the efficiency of a vaccine.
Furthermore, many bio-safety concerns remain unsolved, such as
cases of paralytic polio caused by polio vaccination [54]. An EV71
vaccine can widely be used across the whole of Asia if it is
affordable, easily produced, and readily available. Importantly,
Bac-Pie1-gp64-VP1 vaccine is efficacious in inducing high
neutralization titres, subgenogroup cross-neutralization, and does
not require either sophisticated biocontainment infrastructure or
downstream purification process for mass production. In addition,
the VP1 of any new subgenogroup could be converted into an
efficient vaccine with this technology in a short period of time.
Considering the above facts, we conclude that Bac-Pie1-gp64-VP1
vaccine could be an ideal choice to reduce EV71-associated
morbidity and mortality in the Asia-Pacific region and beyond.
Figure 9. Cross-Neutralization antibodies titers elicited by inactivated virus, Bac-Pph-gp64-VP1 and Bac-pie1-gp64-VP1 in mice at
56 post immunization days against all 11 EV71 subgenogroup strains. Each column represents the arithmetic mean value (n6) 6SD
(p,0.001). *generated viruses from synthetic cDNA; {homogenous strain.
doi:10.1371/journal.pone.0021757.g009
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